A liquid presentation of Leucovorin has been made available by Fresenius Kabi in 100mg/10mL and 500mg/50mL single-use vials. This is currently the only liquid formulation of this agent available in the US.
Leucovorin is indicated for intramuscular or intravenous administration after high-dose methotrexate therapy in osteosarcoma. It is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists.
The drug is also approved to treat megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. When used in combination with 5-fluorouracil, it is indicated to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
“We are pleased to offer a version of Leucovorin Calcium Injection that eliminates the need for reconstitution, providing pharmacists an efficient way to prepare this medication,” said John Ducker, president and CEO of Fresenius Kabi USA.
For more information visit fresenius-kabi.com.